TFW



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

 Application of
 : Esser, F., et al
) Art Unit:
 1626

 U.S. Appln. No.
 : 10/827,408
) Examiner:

Confirmation No. : 2596

U.S. Filing Date : April 19, 2004
Title of Invention : Compounds and Methods for Treating Urinary Incontinence

Attny. Docket No.: 1/1003-4-C3

Mail Stop Amendment Commissioner for Patents P. O. Box 1450 Alexandria, VA 22313-1450

April 21, 2005

TRANSMITTAL LETTER FOR INFORMATION DISCLOSURE STATEMENT

Sir:

Transmitted herewith concerning the subject application is an Information Disclosure Statement (Form 1449A/B) under 37 C.F.R. §§1.56 and 1.97, as more specifically described hereinbelow.

This Statement is being filed: i) within three (3) months of the filing

late of a national application other than a continued prosecution application under 33 C.F.R. lates of a national application other than a continued prosecution application under 33 C.F.R. lat. 33 (d); ii) within three (3) months of the date of entry of the national stage as set forth in 7 C.F.R. §1.491 in an international application; iii) before the mailing of a first Office action in the merits; or iv) before the mailing of a first Office action after the filing of a request for continued examination under 37 C.F.R. §1.114.
1.97(c). This Statement is being filed after the time period specified in 37 C.F.R. §1.97(b), but before the mailing date of: i) a final action under 37 C.F.R. §1.113, ii) a notice of allowance under 37 C.F.R. §1.311, or iii) an action that otherwise closes prosecution the application. This Statement is being accompanied by:
A statement as specified in 37 C.F.R. §1.97(e) [see below]; or
The fee set forth in 37 C.F.R. §1.17(p).

	The Commissioner is hereby authorized to charge payment of the \$180.00 fee set forth in 37 C.F.R. §1.17(p) to Deposit Account No. 02-2955.
21 07/0	1.97(d). This Statement is being filed after the period specified in 37 C.F.R.) but on or before payment of the issue fee. This Statement is accompanied by a mut as specified in 37 C.F.R. §1.97(e) [see below] and the fee set forth in 37 C.F.R.)).
	1.97(e).
	Each item of information contained in the instant information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three (3) months prior to the filing of the instant information disclosure statement; or
	No item of information contained in the instant information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing this certification after making reasonable inquiry, no item of information contained in the instant information disclosure statement was known to any individual designated in 37 C.F.R. §1.56(c) more than three (3) months prior to the filing of the instant information disclosure statement.
	The fee set forth in 37 C.F.R. §1.17(p).
	The Commissioner is hereby authorized to charge payment of the \$180.00 fee set forth in 37 C.F.R. §1.17(p) to Deposit Account No. 02-2955.
in sec	1.704(d). Each item of information contained in the accompanying information source statement was cited in a communication from a foreign patent office in a crepart application, which communication was not received by any individual designated tion 1.56(c) more than thirty (30) days prior to the filing of the accompanying nation disclosure statement.

The Commissioner is hereby authorized to charge payment of any additional filing tees required under 37 C.F.R. §1.16 and any patent application processing fees under 37 C.F.R. §1.17, or credit any overpayment of same, to Deposit Account No. 02-2955.

Triplicate copies of this form are enclosed.

Respectfully submitted,

Timothy X. Witkowski
Attorney for Applicant(s)

Reg. No. 40,232

Patent Department Boehringer Ingelheim Corp. 900 Ridgebury Road, P.O. Box 368 Ridgefield, CT 06877 Tel: (203) 798-4310 Certificate of Mailing

I hereby certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as first class mail in an envelope addressed to:

Mail Stop Amendment Commissioner For Patents P. O. Box 1450 Alexandria, VA 22313-1450

on April 21, 2005

3 of 3

PTO/SB/08a (08-03)
Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPART MENT OF COMMERCE
to a collection of information unless it contains a valid OMB control number.

Under Paperwork Reduction Act of 1995, no persons are required to rescond to a collection of information unless at contains ave Complete if Known

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

 Application Number
 10/827,408

 Filing Date
 April 19, 2004

 First Named Inventor
 Esser, F., et al

 Art Unit
 1626

 Examiner Name
 1626

 (Use as many sheets as necessary)
 Examiner Name

 Sheet
 1
 of
 1
 Attorney Docket Number
 1/1003-4-C3

Examiner Initials*	Cite No.	Number-Kind Code ^{2 (# treown)}	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	L				
		^{US-} 5,480,871	01/02/1996	Spellmeyer, D., et al	
		US-			
	THE OTHER LAND	US-			
		US-	-		
		US-			
		US-			
		US-	-		
		US-			
		US-			
-		US-		The same of the country and the same of th	
		US-			~

	FOREIGN PATENT DOCUMENTS								
Examiner Initials*	Cite No.1	Foreign Patent Document Country Code ³ Number ⁴ Kind Code ⁵ (# known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	т"			
		EP 0464 946	008/01/1992	Akzo N.V.					
	Ī								
	Ī								
•••••••	İ								

Examiner	Date
Signature	Considered

"EXAMINER: Initial if reference considered, whether or not obtation is in conformance with MPEP 603. Draw line through obtation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique classific with properties of the patient of the patient control of the patient of

Intensitation is attached.
This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the This collection of information is required by 35 U.S.C. 122 and 37 CFR 1.4. This collection is settimated by the public which is to file (and by the This collection is settimated by the 2 hours to complete the formation of the collection is settimated by the public of the collection is settimated by the public of the collection is collection in the collection is settimated by the 2 hours of the collection is settimated by the public of the collection is setting the 2 hours of the collection is setting the collection in the collection is setting the collection in the Child in the Child is setting the collection in the Child is setting the child in the Chil